Edition:
United States

WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

36.10USD
2:25pm EDT
Change (% chg)

$-2.10 (-5.50%)
Prev Close
$38.20
Open
$38.45
Day's High
$38.55
Day's Low
$34.75
Volume
134,432
Avg. Vol
56,139
52-wk High
$55.95
52-wk Low
$15.15

Chart for

About

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects... (more)

Overall

Beta: --
Market Cap(Mil.): $1,178.04
Shares Outstanding(Mil.): 29.11
Dividend: --
Yield (%): --

Financials

  WVE.OQ Industry Sector
P/E (TTM): -- 244.89 34.04
EPS (TTM): -4.21 -- --
ROI: -85.64 -5.30 13.11
ROE: -102.39 -6.83 15.11

BRIEF-Wave Life Sciences Reports Qtrly Loss Per Share $1.26

* WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 09 2018

BRIEF-Wave Life Sciences And Deep Genomics Form Collaboration To Discover Therapies For Genetic Neuromuscular Disorders

* WAVE LIFE SCIENCES AND DEEP GENOMICS FORM COLLABORATION TO DISCOVER NOVEL THERAPIES FOR GENETIC NEUROMUSCULAR DISORDERS

Apr 10 2018

BRIEF-Wave Life Ended 2017 With $142.5 Mln In Cash, Equivalents

* WAVE LIFE SCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 12 2018

BRIEF-Wave Life Sciences And Takeda Form Strategic Collaboration To Advance Therapies For Central Nervous System Disorders

* WAVE LIFE SCIENCES AND TAKEDA FORM GLOBAL STRATEGIC COLLABORATION TO ADVANCE THERAPIES FOR CENTRAL NERVOUS SYSTEM DISORDERS

Feb 20 2018

Earnings vs. Estimates